News : phase III

George Köllner joins Syntagon Quality Assurance and regulatory team

1/31/2012 9:35 AM EST - Syntagon

Leading contract research provider, Syntagon, is delighted to announce that it has entered into a collaborative agreement with world-class Quality Assurance (QA) expert George Köllner.
George brings with him more than 20 years’ experience from the pharma industry. He has served as Director of Quality Assurance at AstraZeneca where he led the development and implementation of modern Quality Assurance systems in...

Syntagon Restructures to Further Improve Drug Substance Development Offering

12/22/2011 7:16 AM EST - Syntagon

Leading contract research provider, Syntagon, is set to implement a restructuring programme designed to further improve its offering to customers in the field of drug substance development.
Syntagon’s Sweden-based operations (Syntagon AB) will focus and strengthen its customer-oriented expertise within drug substance development, quality assurance and regulatory support, while the Group’s Latvian site (SIA...

Syntagon Announces New CEO, Changes to Management Team

10/5/2011 8:30 AM EST - Syntagon

Leading contract research organisation, Syntagon, has unveiled important changes to its management team. With immediate effect, Dr. Andis Slaitas will replace Dr. Michael Lofthagen as Syntagon CEO.
Andis has been with Syntagon since 2005 and has been instrumental in developing the Syntagon Baltic site, based in Latvia, into a world-class chemistry facility. Prior to his new position, Andis was VP of operations...

Syntagon Technical Director to Deliver Speech on Guaranteed CMC(s) Approval at C...

9/29/2011 8:00 AM EST - Syntagon

Syntagon’s Technical Director, Dr. Anders Högdin, is set to deliver a presentation entitled "CMC(s) Approval Guaranteed" at the upcoming CPhI Worldwide exhibition in Frankfurt, Germany.
Syntagon is the only CRO that offers Guaranteed CMC(s) approval from regulatory authorities. Dr. Högdin’s speech will explore current regulatory requirements for drug substances in IMPD or IND submission, what the regulatory...

MOBERG DERMA SECURED SEK 35 MILLION IN NEW SHARE ISSUE

8/24/2009 2:00 AM EST - MOBERG DERMA AB

The pharmaceutical company Moberg Derma recently secured SEK 35 million in a new share issue. Both existing and new shareholders subscribed for shares in the issue. More than SEK 100 million has now been raised for its operations since the company was established in March 2006.
“We are very pleased with the interest shown by investors what has been a difficult market climate in recently. The new share issue has...

MOBERG DERMA RECRUITS SALES & MARKETING DIRECTOR

12/9/2008 5:30 AM EST - MOBERG DERMA AB

The Swedish pharmaceutical company Moberg Derma today announces that it is strengthening its organization through the recruitment of Martin Ingman as Sales & Marketing Director.
Martin Ingman will be responsible for building Moberg Derma’s international network of distributors as well as the company’s sales organisation for the Nordic markets. Martin brings 15 years of experience within sales and marketing. His...

MOBERG DERMA REPORTS POSITIVE PHASE III RESULTS FOR K101 AGAINST NAIL FUNGUS

11/20/2008 8:50 AM EST - MOBERG DERMA AB

Moberg Derma AB reports today positive results from a phase III clinical study for K101 against nail fungus (onychomycosis). In the study, almost 500 patients were treated during six months with K101 or a placebo. The results showed that significantly more patients receiving K101 were cured of their fungal infection (p=0.001). The patients' subjective evaluation of the treatment effect revealed distinct benefits...